Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.

The IDS – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for IDS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for IDS and features dormant and discontinued projects.

Key Therapy Areas in the IDS Pipeline Drugs Market

The key therapy areas in the IDS pipeline drugs market are Genetic Disorders, and Central Nervous System.

IDS Pipeline Drugs Market, by Therapy Areas

IDS Pipeline Drugs Market, by Therapy Areas

For more target insights, download a free report sample

Key MoA in the IDS Pipeline Drugs Market

The key mechanisms of action in the IDS pipeline drugs market are Iduronate 2 Sulfatase Activator, and Iduronate 2 Sulfatase Replacement.

IDS Pipeline Drugs Market, by MoA

IDS Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

IDS Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the IDS pipeline drugs market are Subcutaneous, Intravenous, Intracerebral, Intracisternal, Intrathecal, and Parenteral.

IDS Pipeline Drugs Market Analysis, by RoA

IDS Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the IDS Pipeline Drugs Market

The key molecule types in the IDS pipeline drugs market are Recombinant Enzyme, Fusion Protein, Gene Modified Cell Therapy, and Gene Therapy among others.

IDS Pipeline Drugs Market, by Molecule Type

IDS Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the IDS Pipeline Drugs Market

The major companies in the IDS pipeline drugs market are GC Pharma, Homology Medicines Inc, RegenxBio Inc, AVROBIO Inc, AngioChem Inc, Bioasis Technologies Inc, Esteve Pharmaceuticals SA, and Takeda Pharmaceutical Co Ltd among others.

IDS Pipeline Drugs Market, by Major Companies

IDS Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

IDS Pipeline Drugs Market Overview

Key Therapy Areas Genetic Disorders, and Central Nervous System
Key Mechanisms of action Iduronate 2 Sulfatase Activator, and Iduronate 2 Sulfatase Replacement
Key Routes of Administration Subcutaneous, Intravenous, Intracerebral, Intracisternal, Intrathecal, and Parenteral
Key molecule types Recombinant Enzyme, Fusion Protein, Gene Modified Cell Therapy, and Gene Therapy
Major companies GC Pharma, Homology Medicines Inc, RegenxBio Inc, AVROBIO Inc, AngioChem Inc, Bioasis Technologies Inc, Esteve Pharmaceuticals SA, and Takeda Pharmaceutical Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of IDS
  • The pipeline guide reviews pipeline therapeutics for IDS by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in IDS therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates IDS therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for IDS

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for IDS
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding IDS pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC

3.1.6.13) – Overview

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC

3.1.6.13) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC

3.1.6.13) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC

3.1.6.13) – Companies Involved in Therapeutics Development

AngioChem Inc

AVROBIO Inc

Bioasis Technologies Inc

Denali Therapeutics Inc

Esteve Pharmaceuticals SA

GC Pharma

Homology Medicines Inc

Immusoft Corp

JCR Pharmaceuticals Co Ltd

RegenxBio Inc

Sigilon Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC

3.1.6.13) – Drug Profiles

AVRRD-05 – Drug Profile

Product Description

Mechanism Of Action

History of Events

DNL-310 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EGT-301 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II – Drug Profile

Product Description

Mechanism Of Action

History of Events

HMI-203 – Drug Profile

Product Description

Mechanism Of Action

History of Events

idursulfase – Drug Profile

Product Description

Mechanism Of Action

History of Events

idursulfase beta – Drug Profile

Product Description

Mechanism Of Action

History of Events

ISP-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

pabinafusp alfa – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II – Drug Profile

Product Description

Mechanism Of Action

History of Events

RGX-121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SIG-018 – Drug Profile

Product Description

Mechanism Of Action

History of Events

xB-3008 – Drug Profile

Product Description

Mechanism Of Action

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC

3.1.6.13) – Dormant Products

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC

3.1.6.13) – Discontinued Products

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC

3.1.6.13) – Product Development Milestones

Featured News & Press Releases

Feb 15, 2022: JCR announces first patient dosed in phase 3 global clinical trial of JR-141 for treatment of MPS II (Hunter Syndrome)

Feb 10, 2022: Homology medicines announces presentations on HMI-203 investigational gene therapy for Hunter syndrome and broad applicability of AAVHSC platform for lysosomal storage disorders at the 18th Annual WORLDSymposium meeting

Feb 10, 2022: Denali Therapeutics announces continued progress in DNL310 program for MPS II (Hunter Syndrome) supporting planned initiation of Phase 2/3 clinical trial

Feb 09, 2022: REGENXBIO presents additional positive interim data from phase I/II trial of RGX-121 for the treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium 2022

Feb 03, 2022: JCR Pharmaceuticals receives the WORLDSymposium new treatment award for IZCARGO (Pabinafusp Alfa)

Feb 03, 2022: JCR pharmaceuticals to present posters on JR-141 at the 18th annual WORLDSymposium 2022

Feb 01, 2022: Denali therapeutics announces presentations on DNL310 (ETV:IDS) development program in MPS II (hunter syndrome) at the upcoming WORLDsymposium

Nov 29, 2021: Immusoft receives $4M in funding from the California Institute for Regenerative Medicine (CIRM)

Nov 08, 2021: AVROBIO to present preclinical data on AVRRD-05 at the 14th ICIEM Conference

Nov 03, 2021: AVROBIO receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

Nov 02, 2021: GC Green Cross designated as a European orphan drug for the treatment of severe Hunter syndrome

Oct 20, 2021: Homology Medicines announces presentation of data supporting clinical programs in MPS II and PKU, including nonclinical and patient-focused research, at American Society of Human Genetics Meeting

Oct 18, 2021: Homology medicines initiates clinical trial for HMI-203, a one-time investigational gene therapy candidate for adults with MPS II (Hunter Syndrome)

Oct 18, 2021: JCR Pharmaceuticals Co : EMA grants PRIME designation for JR-141 for the treatment of Mucopolysaccharidosis type II (Hunter Syndrome)

Oct 15, 2021: JR-141 (Pabinafusp Alfa) for Hunter syndrome notice on the publication of a nonclinical and clinical evidence in International Journal of Molecular Sciences

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AngioChem Inc, 2022

Pipeline by AVROBIO Inc, 2022

Pipeline by Bioasis Technologies Inc, 2022

Pipeline by Denali Therapeutics Inc, 2022

Pipeline by Esteve Pharmaceuticals SA, 2022

Pipeline by GC Pharma, 2022

Pipeline by Homology Medicines Inc, 2022

Pipeline by Immusoft Corp, 2022

Pipeline by JCR Pharmaceuticals Co Ltd, 2022

Pipeline by RegenxBio Inc, 2022

Pipeline by Sigilon Therapeutics Inc, 2022

Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Dormant Projects, 2022

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.